PofoliaShared via Pofolia

Annals of Translational Medicine· 2020

Global low back pain prevalence and years lived with disability from 1990 to 2017: estimates from the Global Burden of Disease Study 2017

Aimin Wu, Lyn March, Xuan-Qi Zheng, Jinfeng Huang et al.

Short summary

Global low back pain (LBP) prevalence slightly decreased from 8.20% in 1990 to 7.50% in 2017, but the number of affected individuals rose from 377.5 million to 577.0 million. Years lived with disability (YLDs) due to LBP increased by 52.7% from 42.5 million to 64.9 million during the same period.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Global age-standardized LBP prevalence decreased from 8.20% (1990) to 7.50% (2017).
  • The total number of individuals with LBP increased from 377.5 million (1990) to 577.0 million (2017).
  • Global LBP-related YLDs increased by 52.7% from 42.5 million (1990) to 64.9 million (2017).
  • LBP prevalence and YLDs are higher in females than males and increase with age, peaking in older adults for prevalence and mid-adulthood for YLDs.

AI-generated from the title and abstract; the full text is not read.

Abstract

BACKGROUND: Low back pain (LBP) is a common musculoskeletal problem globally. Updating the prevalence and burden of LBP is important for researchers and policy makers. This paper presents, compares and contextualizes the global prevalence and years lived with disability (YLDs) of LBP by age, sex and region, from 1990 to 2017. METHODS: Data were extracted from the GBD (the Global Burden of Disease, Injuries, and Risk Factors Study) 2017 Study. Age, sex and region-specific analyses were conducted to estimate the global prevalence and YLDs of LBP, with the uncertainty intervals (UIs). RESULTS: The age-standardized point prevalence of LBP was 8.20% (95% UI: 7.31-9.10%) in 1990 and decreased slightly to 7.50% (95% UI: 6.75-8.27%) in 2017. The prevalent numbers of people with LBP at any one point in time in 1990 was 377.5 million, and this increased to 577.0 million in 2017. Age-standardized prevalence of LBP was higher in females than males. LBP prevalence increased with age, and peaked around the ages of 80 to 89 years, and then decreased slightly. Global YLDs were 42.5 million (95% UI: 30.2 million-57.2 million) in 1990 and increased by 52.7% to 64.9 million (95% UI: 46.5 million-87.4 million) in 2017. YLDs were also higher in females than males and increased initially with age; they peaked at 35-39 years of age in 1990, before decreasing, whereas in 2017, they peaked at 45-49 years of age, before decreasing. Western Europe had the highest number of LBP YLDs. CONCLUSIONS: Globally, LBP is the leading global cause of YLDs. Greater attention is urgently needed to mitigate this increasing burden and the impact it is having on health and social systems.

The authors' abstract, as published at the source. Annals of Translational Medicine, 2020 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Pharmacology (Medicine)

PharmacologyMedicine